

ORIGINAL RESEARCH ARTICLES

Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort

Stephanie A. Flowers,¹ Simon J. Evans,² Kristen M. Ward,¹ Melvin G. McInnis,² and Vicki L. Ellingrod^{1,2,*}

¹College of Pharmacy, University of Michigan, Ann Arbor, Michigan; ²Department of Psychiatry, University of Michigan, Ann Arbor, Michigan

OBJECTIVES The atypical antipsychotic (AAP) class is often associated with metabolic disease, but the mechanistic underpinnings of this risk are not understood. Due to reports linking gut bacteria function to metabolic disease, we hypothesize that AAP treatment in adults results in gut dysbiosis potentiating metabolic criteria. This report describes recent findings linking AAP treatment with differences in gut microbiota communities in a human cohort with bipolar disorder (BD).

METHODS In a cross-sectional design, we obtained 16S ribosomal sequences from 117 BD patients (49 AAP treated, 68 non-AAP treated). Analysis of molecular variance (AMOVA) was used to detect significant clustering of microbial communities between groups, and the inverse Simpson Diversity Index was used to calculate alpha diversity. Detection of differentially abundant operational taxonomic units (OTUs) between groups was performed using linear discriminant analysis effect size.

RESULTS The AAP-treated cohort was significantly younger and had an increased body mass index compared with non-AAP-treated patients. Groups did not differ in other psychotropic medication use with the exception of higher use of benzodiazepines in the AAP cohort. We detected significant separation between microbiota communities of AAP-treated and nontreated patients (AMOVA; $p=0.04$). AAP-treated females showed significant decreased species diversity when compared with non-AAP-treated females ($p=0.015$). Males showed no significant diversity between treatment groups ($p=0.8$). Differentially abundant OTUs between treatment groups were OTU1, OTU25, and OTU32 that classified to *Lachnospiraceae*, *Akkermansia*, and *Sutterella*, respectively.

CONCLUSIONS These data suggest that AAP treatment is associated with specific representation of gut bacterial families in AAP-treated patients. In addition, AAP treatment is associated with decreased species richness in female AAP-treated patients.

KEY WORDS microbiome, atypical antipsychotics, metabolic disease.

(Pharmacotherapy 2017;37(3):261–267) doi: 10.1002/phar.1890

Manuscript presented in part at the following meetings: (1) Keystone symposia: Gut Microbiota, Metabolic Disorders and Beyond (D4), April 17–21, 2016, Newport, Rhode Island. (2) Society of Biological Psychiatry 71st Annual Scientific Convention, May 12–14, 2016, Atlanta, Georgia.

*Address for correspondence: Vicki L. Ellingrod, College of Pharmacy, University of Michigan, Rm 2060, 428 Church St, Ann Arbor, MI 48109-1065; e-mail: vellingr@med.umich.edu.

© 2017 Pharmacotherapy Publications, Inc.

Patients living with a serious mental illness show significant increases in cardiovascular disease (CVD) and metabolic disease compared with the general population. Up to 30 years of life are lost in this population, primarily due to CVD.¹ For patients receiving an atypical antipsychotic (AAP), the risk of metabolic syndrome is more than twice that seen in the general population.² At least 40% of those taking an AAP meet metabolic syndrome criteria that consist of a

constellation of cardiovascular symptoms that together significantly increase CVD risk.³ In addition, a gender bias exists for AAP-associated CVD risks as seen by a comparison of Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) participants with matched healthy controls from the National Health and Nutrition Examination Survey (NHANES) III.⁴ When investigators examined participants based on the 10-year coronary heart disease risk using the Framingham Heart Study formula, significant differences were seen for elevations in CVD risk (50% females vs 34% males)^{5, 6} and metabolic syndrome (137% more likely in females, 85% more likely in men).⁷ The mechanisms that lead to greater CVD risk in this population have not been defined.

A wealth of data is available pertaining to the role of the gut microbiota in CVD, diabetes, metabolism, and systemic inflammation.^{8, 9} Without prospective studies, it is difficult to determine whether the gut microbiome predisposes patients to these illnesses or if these illnesses modulate the microbiome. Gastric bypass surgery studies show that aside from sustained weight loss, this procedure also precipitates decreased type II diabetes *prior* to any weight decrease.^{10, 11} Furthermore, gastric bypass directly affects glucose regulation, and other studies have cited a shift in microbiota composition, suggesting that the microbiome may improve metabolic function.^{12, 13}

In a recent study of 18 human male adolescents (9–15 years old), chronic use of the AAP risperidone (longer than 1 year) was associated with a microbiome composition exhibiting robust differences from that of nonmedicated controls.¹³ Chronic risperidone-treated patients showed increased relative representation of the Firmicutes phylum, especially in those with increased body mass index (BMI). In addition, a longitudinal investigation in five males revealed a gradual change in gut microbiota composition and a simultaneous increase in BMI during the months following the onset of risperidone treatment.¹³ In rat models, studies of olanzapine treatment had significant effects on a number of physiologic, inflammatory, and microbial parameters that were more pronounced in female rats compared with males.^{14–16} Specific microbiome alterations in olanzapine-treated female rats included overall decreased biodiversity and increased macrophage infiltration in adipose tissue.¹⁴ In a follow-up study, coadministration of antibiotics attenuated the physiologic and inflammatory effects of olanzapine use.¹⁶

The purpose of this study was to determine if treatment-specific differences in gut microbe communities were detectable in a well-characterized cohort of patients with a serious mental illness. We hypothesized that AAP treatment would associate with a significant separation in fecal microbiota communities from bipolar disorder (BD) patients treated with AAPs compared with those patients with BD not treated with AAPs.

Methods

Participants

The Prechter Longitudinal Study of Bipolar Disorder is an ongoing observational study of BD at the University of Michigan (HUM00000606).¹⁷ Medication group for each patient was defined by the use of an AAP at the time of fecal sample collection. Atypical antipsychotics included in our cohort were clozapine, olanzapine, risperidone, quetiapine, asenipine, ziprasodone, lurasidone, aripiprazole, paliperidone, and iloperidone. Neither group differed in treatment with mood stabilizers or antidepressants (Table 1). The AAP-treatment group proportionally used more benzodiazepines. In addition to medication, we also noted age, BMI, and gender for these patients.

Table 1. Demographic Characteristics at Baseline

	No AAP ^a N (%) or mean (SD)	AAP ^a N (%) or mean (SD)	p value
Gender			
Female	48	34	0.82
Male	21	12	
Age, yrs (SD)	51.7 (13.5)	46 (12)	0.02
Body mass index (SD)	27.5 (6)	31 (7)	0.006
Body mass index corrected by age and gender			0.04
Medications			
Antidepressant ^b (%)	26 (38)	26 (53)	0.16
Mood stabilizer ^c (%)	32 (47)	28 (57)	0.37
Lithium (%)	20 (29)	11 (22)	0.53
Benzodiazepine ^d (%)	13 (19)	19 (39)	0.03

^aAAP = atypical antipsychotic (clozapine, olanzapine, risperidone, quetiapine, asenipine, ziprasodone, lurasidone, aripiprazole, paliperidone, and iloperidone).

^bAntidepressant = bupropion, venlafaxine, sertraline, duloxetine, fluoxetine, citalopram, escitalopram.

^cMood stabilizer = topiramate, phenobarbital, lamotrigine, gabapentin, divalproex sodium, carbamazepine.

^dBenzodiazepine = lorazepam, alprazolam, temazepam, clonazepam, diazepam.

Fecal Collection and Processing

One fecal sample from each patient was collected using the OMNIgene-Gut kit OMR-200 (DNA Genotek, Kanata, ON, Canada). Total DNA was isolated from 250 μ L of the fecal sample using the PowerMag soil DNA isolation kit (MoBio, Carlsbad, CA), optimized for Eppendorf's epMotion liquid handling robot (Hauppauge, NY).

Sequencing

The DNA libraries were prepared by the Microbiome Core at the University of Michigan as described previously.¹⁸ The bacterial V4 16S rRNA region was amplified with a barcoded primer set using the Schloss protocol.¹⁸ Approximately 5 μ L of a 4 μ M dual index primer stock, 0.15 μ L AccuPrime High-Fidelity Taq, 2 μ L 10 \times AccuPrime PCR II buffer (Life Technologies, Carlsbad, CA), 11.85 μ L polymerase chain reaction (PCR)-grade water, and 1 μ L template were used in the PCR reaction, which was also spiked with 10% PhiX for diversity. The cycling conditions for PCR were as follows: 95°C for 2 minutes, 30 cycles of 95°C for 20 seconds, 55°C for 15 seconds, and 72°C for 5 minutes, followed by 10 minutes at 72°C. Amplified DNA was sequenced using Illumina MiSeq V2 chemistry (Illumina Inc., San Diego, CA).

Data Processing and Analysis

Sequence files were processed with mothur v.1.36.0 using the described operating procedure.¹⁸ Assembled contigs were filtered for chimeric sequences using UCHIME¹⁹ and aligned to a mothur-adapted RDB database. A 97% cutoff was used to bin sequences into operational taxonomic units (OTUs). A complete list of commands for data processing, statistical analysis, and data presentation are available at https://github.com/StephanieAFlowers/Evans_Microbiome.

Statistics

Microbiome 16S sequencing data were analyzed using a combination of the software programs mothur (v.1.38.6, University of Michigan, Ann Arbor, MI; see reference 18) and R v3.2.5 (R Foundation for Statistical Computing, Vienna, Austria). Demographic and microbial differences between treatment groups were determined

through the use of standard *t* tests, χ^2 tests, Wilcoxon tests, and Spearman correlations. Differences in BMI between treatment groups (AAP treated vs non-AAP treated) were adjusted for known BMI predictors such as age and gender. We used analysis of molecular variance (AMOVA) to compare microbial communities between medication groups. Differentially abundant OTUs between treatment groups were identified using linear discriminant analysis (LDA) effect size (LEfSe) analysis. For significant OTUs defined by LEfSe analysis, we performed a regression to adjust for age, BMI, and gender. Alpha diversity for each patient was measured using an inverse Simpson diversity estimate. The second linear regression was adjusted for age, BMI, and benzodiazepine use but compared diversity estimates with medication and gender cohorts.

Results

Participant Demographics

Our BD cohort comprised 117 adults with BD from the Prechter Longitudinal Study of Bipolar Disorder. Among the 117, 49 were treated with an AAP and 68 were not (Table 1). Significant demographic differences at baseline between medication groups included an older population that did not receive AAP treatment ($p=0.02$) and higher BMI values in AAP users that remained significant after correcting for age and gender ($p=0.04$). No significant differences in treatment with lithium or mood stabilizers were noted between the medication cohorts. The AAP-treated population had a greater use of benzodiazepines.

To investigate differences between the fecal communities of AAP-treated and non-AAP-treated participants, we calculated the beta diversity using the Yue and Clayton distance (θ YC).²⁰ Principal coordinates analysis (PCoA) from the θ YC calculated distances revealed significant separation between the two medication groups using AMOVA (Figure 1; $p=0.04$).²¹ A biplot illustrating OTUs associating toward PCoA axes 1 and 2 showed three OTUs responsible for differing directions of the two medication cohorts: OTU1 (classified as *Lachnospiraceae*), OTU11 (classified as *Alistipes*), and OTU25 (classified as *Akkermansia*).

Differentially abundant OTUs were identified using LDA LEfSe.²² LEfSe revealed three differentially represented OTUs between our medication groups that were in the top 50 abundant




Figure 1. Gut community structure in BD patients with or without AAP treatment. PCoA was used to plot the Yue and Clayton dissimilarity index (θ YC; AMOVA = 0.04). AAP = atypical antipsychotic; AMOVA = analysis of molecular variance; BD = bipolar disorder; OTU = operational taxonomic unit; PCoA = principal coordinate analysis.




Figure 2. Differentially abundant members of gut microbiota in BD patients treated with AAPs (blue) and not treated with AAPs (yellow). The mean relative abundance plus standard error of differentially abundant OTUs identified by LEfSe. AAP = atypical antipsychotic; BD = bipolar disorder; OTU = operational taxonomic unit.

taxonomic units (Figure 2). OTU1 classified to *Lachnospiraceae*, and OTU25 and OTU32 classified to *Akkermansia* and *Sutterella*, respectively. *Lachnospiraceae*, or OTU1, was the only differen-

tially abundant OTU identified as preferentially increased in patients treated with AAPs. OTUs25 and 32 were preferentially abundant in the group that was not treated with AAPs. Because our medication cohorts differed in both age and BMI, we performed linear regressions for the relative abundance of OTUs1, 25, and 32 between medication groups adjusting for age, BMI, and gender. Only OTUs1 and 25 remained significant ($p=0.001$ and $p=0.03$) after these adjustments.

Due to established associations between OTU1 (classified to *Lachnospiraceae*) and OTU25 (classified to *Akkermansia*) and metabolic criteria, we further explored the interaction between BMI and AAP treatments in regard to observed relative abundance (Figure 3).^{23, 24} When considering the obese (BMI of 30 or higher) and non-obese populations independently, we observed no appreciable differences in relative abundance of OTU1 between AAP and non-AAP-treated populations. When independently comparing obese and nonobese populations for differences in relative abundance of OTU25, we observed no difference between medication groups in the obese population. However, when examining the relative abundance of OTU25 in the nonobese, we observed a significant decrease in OTU25 in those treated with AAPs.

A significant decrease in microbiome community diversity for AAP-treated patients was revealed when calculating the inverse Simpson Diversity Index between the medication treatment cohorts (Figure 4A; $p=0.045$). When stratified by gender, we detected a greater decrease in diversity for AAP-treated females compared with non-AAP-treated females (Figure 4B; $p=0.015$). No significant difference in diversity was found in male patients (Figure 4C; $p=0.8$). Differences in microbiota diversity between the female medication cohorts remained significant after adjusting for age, BMI, and benzodiazepine treatment ($p=0.02$, $\beta=-4.6$, $R^2=0.12$).

Discussion

Although the pathogenesis of AAP-associated metabolic disease is undoubtedly multifactorial, the contribution of the gut to this phenotype is an avenue worth investigating. Our current study revealed a significant separation between fecal microbiota communities and differentially abundant OTUs between the two medication cohorts. Of particular interest, OTU25, *Akkermansia*, was significantly decreased in nonobese patients treated with AAPs. *Akkermansia* is a




Figure 3. Interaction of AAP use and BMI on relative abundance of OTU1 and OTU25. The A panels show all patient data differentiated by medication group. The B panels reflect data from all patients differentiated by an obese BMI (BMI>30). The C panels show the relative abundance of each OTU differentiated by medication group in only the obese patients. The D panels show the relative abundance of each OTU differentiated by medication group in only the nonobese patients. AAP = atypical antipsychotic; BMI = body mass index; OTU = operational taxonomic unit.

monotypic genus in the branched phylum *Verrucomicrobia*, with *A. muciniphila* as its only species. *A. muciniphila* is a mucin degrader in the intestinal tract and has a notable inverse association with inflammation, insulin resistance, altered adipose metabolism, and atherosclerosis.^{24–26} Data suggest that in response to AAPs without increases in BMI, both human and animal models incur metabolic phenotypes such as glucose dysregulation.²⁷ This makes the decreased relative abundance of *A. muciniphila* in nonobese patients notable.

We also observed a significant decrease in species diversity for the AAP-treated cohort, a

correlation that was stronger in AAP-treated females. Gut species diversity is often cited as a marker of gut health because it is decreased in a number of populations with metabolic syndrome risk factors such as obesity or diabetes.²⁸ Relevant to our findings, rat models of antipsychotic-induced weight gain and microbiome analysis also show a gender bias in which female rats experience greater weight gain and microbiota community differences than do males.^{14, 29, 30} Although our cohort was underpowered for male patients to investigate gender differences in medication response properly, a previous publication looking at microbiome changes in males observed




Figure 4. Fecal microbiota diversity as measured by inverse Simpson diversity index () in AAP-treated (yes) and non-AAP treated (no) patients with bipolar disease. A) Diversity between AAP- and non-AAP-treated patients of both genders. B) Comparison of diversity between AAP- and non-AAP-treated female patients ($p = 0.015$; Wilcoxon). C) Comparison of diversity between AAP- and non-AAP-treated male patients ($p=0.8$; Wilcoxon). AAP = atypical antipsychotic; OTU = operational taxonomic unit.

an increase in gut microbiota diversity in those treated with AAPs.¹³

This report contains some clear limitations. AAP-induced metabolic disease has a greater association with specific agents within this class.⁷ However, there was not enough power to examine the effects of specific agents on microbial communities. Generally, the addition of an AAP in BD may indicate increased seriousness of disease, which could also affect the gut microbiota community. In future work, it may be prudent to investigate the effects of this class of medications in different disease cohorts. This report included no information regarding diet, which is an important environmental factor that drives the composition of gut microbiota. In humans, AAPs are thought to induce weight gain through increased appetite,^{31, 32} but this was not borne out in our previous work comparing diets in AAP-treated patients with schizophrenia and normal controls using the NHANES database.³³ Although the schizophrenia cohort showed an increase in smoking, we found the patients with schizophrenia consumed fewer total calories, carbohydrates, and fats, as well as more fiber ($p<0.03$) when compared with NHANES controls. Therefore, simply relating the metabolic complications seen from AAP to diet intake fails to truly understand this relationship.

Finally, stool is often sampled to examine gut microbiota due to the ease of collection. However, it is not clear to what degree the composition of fecal microbiota relates to the function of

microbiota in the gut and microbiota in the intestinal mucosa. Short-chain fatty acids are metabolic products of microbiome fermentation, and the presence of these microbial-derived metabolites has been correlated with many health benefits.³⁴ Although we did observe medication-specific microbiota differences in our cohort, it is not known how these translate into functional differences from the microbiome communities. In the future, obtaining this information will give us critical insight into how AAP-specific changes in microbiome composition affect microbiome output and, ultimately, host phenotype.

In conclusion, these data support our hypothesis that AAP treatment results in measurable differences in gut microbiota composition in a well-characterized group of patients with BD.

Acknowledgments

This work is supported by the Heinz C. Prechter Bipolar Research Fund and the Richard Tam Foundation at the University of Michigan Depression Center. This work is also supported by grants from the National Institute for Mental Health under Award Number R01MH082784.

References

- Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. *Prev Chronic Dis* 2006;3(2):A42.
- Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005;353(12):1209–23.
- National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. *Circulation*. 2002;106(25):3143–421.
- McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. *Schizophr Res* 2005;80(1):19–32.
- Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. *Schizophr Res* 2008;105(1–3):175–87.
- Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. *Schizophr Res* 2005;80(1):45–53.
- Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. *Schizophr Res* 2008;101(1–3):273–86.
- Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. *Science* 2005;307(5717):1915–20.

9. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 2006;444(7122):1027–31.
10. Cho YM. A gut feeling to cure diabetes: potential mechanisms of diabetes remission after bariatric surgery. *Diabetes Metab J* 2014;38(6):406–15.
11. Elahi D, Galiatsatos P, Rabiee A, et al. Mechanisms of type 2 diabetes resolution after Roux-en-Y gastric bypass. *Surg Obes Relat Dis* 2014;10(6):1028–39.
12. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. *JAMA* 2004;292(14):1724–37.
13. Bahr SM, Tyler BC, Wooldridge N, et al. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. *Transl Psychiatry* 2015;5:e652.
14. Davey KJ, O'Mahony SM, Schellekens H, et al. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. *Psychopharmacology* 2012;221(1):155–69.
15. Morgan AP, Crowley JJ, Nonneman RJ, et al. The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse. *PLoS ONE* 2014;9(12):e115225.
16. Davey KJ, Cotter PD, O'Sullivan O, et al. Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. *Transl Psychiat* 2013;3:e309.
17. Flowers SA, Ryan KA, Lai Z, McInnis MG, Ellingrod VL. Interaction between COMT rs5993883 and second generation antipsychotics is linked to decreases in verbal cognition and cognitive control in bipolar disorder. *BMC Psychol* 2016;4:14.
18. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. *Appl Environ Microbiol* 2009;75(23):7537–41.
19. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. *Bioinformatics* 2011;27(16):2194–200.
20. Yue JC, Clayton MK. A similarity measure based on species proportions. *Commun Stat Theor Methods* 2005;34:2123–31.
21. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. *Genome Biol* 2011;12(6):R60.
22. Excoffier L, Smouse PE, Quattro JM. Analysis of molecular variance inferred from metric distances among DNA haplotypes: application to human mitochondrial DNA restriction data. *Genetics* 1992;131(2):479–91.
23. Kameyama K, Itoh K. Intestinal colonization by a *Lachnospiraceae* bacterium contributes to the development of diabetes in obese mice. *Microbes Environ* 2014;29(4):427–30.
24. Schneeberger M, Everard A, Gómez-Valadés AG, et al. *Akkermansia muciniphila* inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. *Sci Rep* 2015;5:16643.
25. Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. *Akkermansia muciniphila* protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in ApoE^{-/-} mice. *Circulation* 2016;133(24):2434–46.
26. Everard A, Belzer C, Geurts L, et al. Cross-talk between *Akkermansia muciniphila* and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci USA* 2013;110(22):9066–71.
27. Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. *Diabetes* 2013;62(9):3232–40.
28. Hugon P, Lagier JC, Colson P, Bittar F, Raoult D. Repertoire of human gut microbes. *Microb Pathog* [Published online ahead of print June 16, 2016]. Available from <http://dx.doi.org/10.1016/j.micpath.2016.06.020>.
29. Aichhorn W, Marksteiner J, Walch T, et al. Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. *J Child Adolesc Psychopharmacol* 2007;17(5):665–74.
30. Haack S1, Seeringer A, Thürmann PA, Becker T, Kirchheiner J. Sex-specific differences in side effects of psychotropic drugs: genes or gender? *Pharmacogenomics* 2009;10(9):1511–26.
31. Smith RC, Rachakonda S, Dwivedi S, Davis JM. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients. *Psychiatry Res* 2012;199:159–63.
32. Teff KL, Kim SF. Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism. *Physiol Behav* 2011;104(4):590–8.
33. Bly MJ, Taylor SF, Dalack G, et al. Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. *Bipolar Disord* 2014;16(3):277–88.
34. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. *J Clin Gastroenterol* 2006;40(3):235–43.